Joinn Laboratories(China)Co (603127) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥145.13 Million ≈ $21.24 Million USD) by net assets (CN¥8.12 Billion ≈ $1.19 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 603127 market cap overview for the company's overall valuation and market capitalisation.
Joinn Laboratories(China)Co - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Joinn Laboratories(China)Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Joinn Laboratories(China)Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Joinn Laboratories(China)Co ranked by their cash flow conversion efficiency. Explore Joinn Laboratories(China)Co earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Integer Holdings Corp
NYSE:ITGR
|
0.035x |
|
Huber+suhner AG
SW:HUBN
|
0.096x |
|
Seazen Holdings Co Ltd
SHG:601155
|
0.003x |
|
JK Cement Limited
NSE:JKCEMENT
|
0.072x |
|
OPENLANE, Inc.
NYSE:OPLN
|
0.135x |
|
Magnolia Oil & Gas Corp
NYSE:MGY
|
0.123x |
|
Patterson-UTI Energy Inc
NASDAQ:PTEN
|
0.018x |
|
Ningbo Joyson Electronic Corp
SHG:600699
|
0.074x |
Annual Cash Flow Conversion Efficiency for Joinn Laboratories(China)Co (2012–2025)
The table below shows the annual cash flow conversion efficiency of Joinn Laboratories(China)Co from 2012 to 2025. View Joinn Laboratories(China)Co stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
CN¥444.57 Million ≈ $65.05 Million |
0.053x | +27.29% |
| 2024-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
CN¥338.93 Million ≈ $49.60 Million |
0.042x | -46.37% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
CN¥647.73 Million ≈ $94.78 Million |
0.078x | -34.02% |
| 2022-12-31 | CN¥8.19 Billion ≈ $1.20 Billion |
CN¥971.07 Million ≈ $142.10 Million |
0.119x | +23.53% |
| 2021-12-31 | CN¥7.14 Billion ≈ $1.05 Billion |
CN¥685.66 Million ≈ $100.33 Million |
0.096x | -72.58% |
| 2020-12-31 | CN¥1.22 Billion ≈ $179.13 Million |
CN¥428.39 Million ≈ $62.69 Million |
0.350x | +95.48% |
| 2019-12-31 | CN¥827.26 Million ≈ $121.05 Million |
CN¥148.09 Million ≈ $21.67 Million |
0.179x | -33.76% |
| 2018-12-31 | CN¥651.52 Million ≈ $95.34 Million |
CN¥176.08 Million ≈ $25.77 Million |
0.270x | +25.61% |
| 2017-12-31 | CN¥557.79 Million ≈ $81.62 Million |
CN¥120.01 Million ≈ $17.56 Million |
0.215x | -52.89% |
| 2016-12-31 | CN¥260.18 Million ≈ $38.07 Million |
CN¥118.82 Million ≈ $17.39 Million |
0.457x | -10.43% |
| 2015-12-31 | CN¥208.35 Million ≈ $30.49 Million |
CN¥106.23 Million ≈ $15.54 Million |
0.510x | -1.55% |
| 2014-12-31 | CN¥159.07 Million ≈ $23.28 Million |
CN¥82.38 Million ≈ $12.05 Million |
0.518x | +3.63% |
| 2013-12-31 | CN¥121.89 Million ≈ $17.84 Million |
CN¥60.91 Million ≈ $8.91 Million |
0.500x | +143.98% |
| 2012-12-31 | CN¥99.27 Million ≈ $14.53 Million |
CN¥20.33 Million ≈ $2.98 Million |
0.205x | -- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more